上市COVID-19疫苗之相關專利資訊
Pfizer/BioNTech
已上市疫苗:BNT162b2
Moderna
已上市疫苗:mRNA-1273
已上市疫苗:BNT162b2
| 發明名稱 | 技術內容 | 重點技術 |
| Preparation and Storage of Liposomal RNAFormulations Suitable for Therapy (適用於治療之微脂體ＲＮＡ配製物的製備及儲存) |
US 2020/0246267 | Lipids/NP + mRNA |
| (TW201927288) | ||
| Particles Comprising a Shell with RNA | US 10576146 | Lipids/NP + mRNA |
| RNA Formulation for Immunotherapy | US 10485884 | Lipids/NP + mRNA |
| Particles Comprising a Shell with RNA | US 9950065 | Lipids/NP + mRNA |
| Particles Comprising a Shell with RNA | US 2020/0155671 | Lipids/NP + mRNA |
| Methods and Compositions for Stimulating Immune Response | US 2020/0197508 | RNA immune response |
| Method for Reducing Immunogenicity of RNA | US 10808242 | RNA immunogenicity |
| Formulation for Administration of RNA | US 2019/0321458 | PC: Lipids/NP + mRNA |
| Lipid Particle Formulations for Delivery of RNA and Water-Soluble Therapeutically Effective Compounds to a Target Cell | US 11045418 | Lipids/NP + mRNA |
| Stable Formulations of Lipids and Liposomes | US 2017/0273907 | Lipids/NP + mRNA |
| Method for Cellular RNA Expression | US 2014/0030808 | RNA expression |
| Particles Comprising Single Stranded RNA and Double Stranded RNA for Immunomodulation | US 9636414 | Lipids/NP + mRNA |
Moderna
已上市疫苗:mRNA-1273
| 發明名稱 | 技術內容 | 重點技術 |
| Respiratory Virus Vaccines (呼吸道病毒疫苗) | US 10702600 | Cationic Lipids/NP + mRNA |
| (TW201729835) | ||
| Compounds and Compositions for Intracellular Delivery of Therapeutic Agents (用於細胞內遞送治療劑之化合物及組合 物) | US 10266485 | Lipids/NP + mRNA |
| US 10442756 | ||
| US 9868692 | ||
| (TW201718017) | ||
| Modified Polynucleotides for the Production of Secreted Proteins | US 10577403 | Lipids/ NP |
| US 10703789 |
